MedTrace Logo

Role of Nefopam in Rituximab Transfusion Reaction

NCT05648058 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-12-15

No results posted yet for this study

Summary

the patients will be taken nefopam ampule 50 mg before rituximab in the first group while the second group will be taken diphenhydramine ampule 10 mg before rituximab in the second group

Conditions

  • Nefopam

Interventions

DRUG

Nefopam ampule

nefopam ampule 50 mg

DRUG

diphenhydramine ampule

diphenhydramine ampule 10 mg

Sponsors & Collaborators

  • Ministry Of Health / Nineveh Health Directorate

    lead OTHER_GOV

Principal Investigators

  • moataz alani · Ministry Of Health / Nineveh Health Directorate

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-20
Primary Completion
2023-10-20
Completion
2023-11-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05648058 on ClinicalTrials.gov